gci

Current Issue cover

Inter Parfums' Estimated 2021 Net Sales to Exceed $610 Million

Contact Author
Close
Fill out my online form.

Inter Parfums is starting its 2021 launch schedule with its Kate Spade signature scent.

Inter Parfums, Inc. has announced that its expected 2021 net sales to be in the range of $610 million and $625 million per diluted share of between $1.20 and $1.25. This represents a 24.1% increase in net sales compared to 2020.

Related: Inter Parfums' 2020 Q3 and 9-month Results

Jean Madar, chairman & CEO of Inter Parfums, Inc. said, “After a near suspension of new product introductions in 2020, we are jumpstarting our 2021 launch schedule with our Kate Spade signature scent, which previewed on Ulta’s online platform in mid-November, followed by Macys.com and katespade.com in mid-December. That is also when our ad campaign begins with actress, dancer and model Maddie Ziegler, the face of the brand’s new fragrance. Before 2020 year-end, the over 1,200 Ulta stores will begin selling the fragrance, and early in the new year, the scent will rollout in major U.S. department stores plus Amazon, and major European markets. Come the second quarter, distribution will include Asia, the Middle East and Latin America.”

Madar further noted, “Also in the first half of 2021, we have rollouts coming for our initial MCM women’s fragrance, Jimmy Choo’s I Want Choo, GUESS’s Bella Vita, the Canyon Ranch duo for Hollister, a new pillar for Abercrombie & Fitch, Oscar de la Renta’s Alibi and Driven by Dunhill. This is in addition to an extension for our largest brand, Montblanc, and its growing Legend family, as well as the relaunch of Lesedi La Rona collection under the Graff label. In the second half of the year, we have new women’s scents debuting for Lanvin, Rochas and the long-awaited introduction of Sky, by Anna Sui.”

Madar concluded, "After a subdued 2020 in terms of advertising and promotion, we are putting muscle behind our major brands and important launches in 2021. With the expectation of effective, safe and widely distributed COVID-19 vaccines, we look forward to regrowing our sales and restoring the operating leverage inherent in our business model, knowing that the road ahead may have some speed bumps along the way. Our plans for the future echo the past, namely to establish fragrance dynasties from among our best sellers, continually refresh our brands by developing and launching new products, add new licenses that fill an untapped opportunity within our portfolio, and expand the distribution of our products, especially through e-commerce." 

Related Content